Collins Otieno

Changes in neurodevelopmental outcomes from 24 to 36 months among children HIV-exposed uninfected (CHEU) and HIV-unexposed (CHU)

Objective: To compare neurodevelopment through 36 months between breastfed children who are HIV-exposed and uninfected (CHEU) exposed to maternal dolutegravir (DTG)-based antiretroviral therapy (ART) and children born to mothers without HIV (CHU). Methods: We enrolled a prospecti...